Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.
Cheng Xu(Sun Yat-sen University), Jun Ma(Shanghai Institute of Technology), Changjuan Tao(Zhejiang Cancer Hospital), Xiaozhong Chen(Tokyo Institute of Technology), Shubin Hong(Sun Yat-sen University), Guan‐Qun Zhou(Sun Yat-sen University), Yuan Wu(UPMC Hillman Cancer Center), Gang Peng(University School), Ying Sun(Key Laboratory of Guangdong Province), Kunyu Yang(Macau University of Science and Technology), Shaojun Lin(Fujian Provincial Cancer Hospital), Jing Huang(Wuhan National Laboratory for Optoelectronics), Hong-Yun Zhao(Sun Yat-sen University), Desheng Hu(Hubei Cancer Hospital), Qin Zhou(Central South University), Feng Jin(Guiyang Medical University), Wen‐Fei Li(Sun Yat-sen University), Liangfang Shen(Central South University), Hui-Ling Huang(Sun Yat-sen University), Jibin Li(State Key Laboratory of Pollution Control and Resource Reuse)
Cited by 0
Related Papers
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
A Metagenomic Approach to Characterization of the Vaginal Microbiome Signature in Pregnancy
|PLoS ONE|2012|703
Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma
|Cell Research|2020|483
Long Noncoding RNA FAM225A Promotes Nasopharyngeal Carcinoma Tumorigenesis and Metastasis by Acting as ceRNA to Sponge miR-590-3p/miR-1275 and Upregulate ITGB3
|Cancer Research|2019|423
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline
|Journal of Clinical Oncology|2021|393